Journal
SCIENCE
Volume 372, Issue 6538, Pages -Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.abf2022
Keywords
-
Categories
Funding
- Institut National de la Sante et de la Recherche Medicale (INSERM) ATIP-Avenir program
- INSERM-Region Occitanie
- European Research Council (ERC)-Seventh Framework Program [ERC-2013-CoG 616050]
- Institut Pasteur
- INSERM
- Societe Francaise de Dermatologie (SFD)
- Societe Francaise d'Allergologie (SFA)
- Marie Sklodowska-Curie Individual Fellowship [749629]
- European Research Council [802041]
- INSERM ATIP-Avenir program
- Chancellor's Fellowship of the University of Edinburgh
- Kennedy Trust for Rheumatology Research
- Marie Curie Actions (MSCA) [749629] Funding Source: Marie Curie Actions (MSCA)
- European Research Council (ERC) [802041] Funding Source: European Research Council (ERC)
Ask authors/readers for more resources
The researchers found that interleukin-33 can induce accumulation of tumor-associated macrophages expressing the Fc epsilon RI receptor, but raised concerns about the specificity of the anti-Fc epsilon RI antibody used in the study.
Taniguchi et al. (Research Articles, 17 July 2020, p. 269) claim that the cytokine interleukin-33 induces accumulation of tumor-associated macrophages expressing the immunoglobulin E receptor Fc epsilon RI. Although these findings hold great therapeutic promise, we provide evidence that the anti-Fc epsilon RI antibody used in this study is not specific for Fc epsilon RI on macrophages, which raises concerns about the validity of some of the conclusions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
